Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced the publication of Phase 3 TRANSCEND trial results for setmelanotide in The New England Journal of Medicine, demonstrating robust efficacy in patients with acquired hypothalamic obesity. Patients treated with setmelanotide achieved a 19.8% placebo-adjusted reduction in BMI at 52 weeks, with 80% of participants achieving at least 5% BMI reduction compared to placebo.
Key figures
- Primary cohort n
- 120
- Mean bmi change placebo
- +3.3%
- Statistical significance
- p<0.0001
- Mean bmi reduction treatment
- -16.5%
- Placebo adjusted bmi reduction
- -19.8%
- Patients 5 percent bmi reduction
- 80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.